We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Steris (STE) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
The upcoming report from Steris (STE - Free Report) is expected to reveal quarterly earnings of $2.38 per share, indicating an increase of 11.2% compared to the year-ago period. Analysts forecast revenues of $1.43 billion, representing an increase of 7.4% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Steris metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts' assessment points toward 'Revenues- Healthcare' reaching $1.01 billion. The estimate indicates a year-over-year change of +6.9%.
The consensus among analysts is that 'Revenues- Healthcare Products- Service' will reach $374.76 million. The estimate suggests a change of +6.2% year over year.
The consensus estimate for 'Revenues- Healthcare Products- Capital Equipment' stands at $268.96 million. The estimate indicates a change of +7.7% from the prior-year quarter.
Analysts forecast 'Revenues- Healthcare Products- Consumables' to reach $357.50 million. The estimate indicates a year-over-year change of +4.6%.
Analysts expect 'Revenues- Applied Sterilization Technologies (AST)' to come in at $281.02 million. The estimate indicates a change of +9.5% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Life Sciences' will reach $137.24 million. The estimate indicates a year-over-year change of +7.3%.
The average prediction of analysts places 'Revenues- Service' at $701.59 million. The estimate suggests a change of +10.8% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Product' of $724.60 million. The estimate points to a change of +4.1% from the year-ago quarter.
Analysts predict that the 'Revenues- Life Sciences- Service' will reach $36.79 million. The estimate indicates a year-over-year change of +12.1%.
According to the collective judgment of analysts, 'Revenues- Life Sciences- Consumables' should come in at $71.75 million. The estimate indicates a year-over-year change of -0.5%.
The combined assessment of analysts suggests that 'Revenues- Life Sciences- Capital Equipment' will likely reach $27.85 million. The estimate indicates a change of +21% from the prior-year quarter.
Based on the collective assessment of analysts, 'Operating income / (loss)- Healthcare' should arrive at $239.46 million. The estimate is in contrast to the year-ago figure of $228.01 million.
Shares of Steris have demonstrated returns of -1.4% over the past month compared to the Zacks S&P 500 composite's +2.1% change. With a Zacks Rank #4 (Sell), STE is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to Steris (STE) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
The upcoming report from Steris (STE - Free Report) is expected to reveal quarterly earnings of $2.38 per share, indicating an increase of 11.2% compared to the year-ago period. Analysts forecast revenues of $1.43 billion, representing an increase of 7.4% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Steris metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts' assessment points toward 'Revenues- Healthcare' reaching $1.01 billion. The estimate indicates a year-over-year change of +6.9%.
The consensus among analysts is that 'Revenues- Healthcare Products- Service' will reach $374.76 million. The estimate suggests a change of +6.2% year over year.
The consensus estimate for 'Revenues- Healthcare Products- Capital Equipment' stands at $268.96 million. The estimate indicates a change of +7.7% from the prior-year quarter.
Analysts forecast 'Revenues- Healthcare Products- Consumables' to reach $357.50 million. The estimate indicates a year-over-year change of +4.6%.
Analysts expect 'Revenues- Applied Sterilization Technologies (AST)' to come in at $281.02 million. The estimate indicates a change of +9.5% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Life Sciences' will reach $137.24 million. The estimate indicates a year-over-year change of +7.3%.
The average prediction of analysts places 'Revenues- Service' at $701.59 million. The estimate suggests a change of +10.8% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Product' of $724.60 million. The estimate points to a change of +4.1% from the year-ago quarter.
Analysts predict that the 'Revenues- Life Sciences- Service' will reach $36.79 million. The estimate indicates a year-over-year change of +12.1%.
According to the collective judgment of analysts, 'Revenues- Life Sciences- Consumables' should come in at $71.75 million. The estimate indicates a year-over-year change of -0.5%.
The combined assessment of analysts suggests that 'Revenues- Life Sciences- Capital Equipment' will likely reach $27.85 million. The estimate indicates a change of +21% from the prior-year quarter.
Based on the collective assessment of analysts, 'Operating income / (loss)- Healthcare' should arrive at $239.46 million. The estimate is in contrast to the year-ago figure of $228.01 million.
View all Key Company Metrics for Steris here>>>Shares of Steris have demonstrated returns of -1.4% over the past month compared to the Zacks S&P 500 composite's +2.1% change. With a Zacks Rank #4 (Sell), STE is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .